BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36672339)

  • 21. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
    Okamura Y; Ashida R; Ito T; Sugiura T; Mori K; Uesaka K
    Surg Today; 2015 Dec; 45(12):1513-20. PubMed ID: 25527455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma.
    Sassa T; Kumada T; Nakano S; Uematsu T
    Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
    Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I
    Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma.
    Núñez KG; Sandow T; Fort D; Patel J; Hibino M; Carmody I; Cohen AJ; Thevenot P
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic value of alpha-fetoprotein,
    Song T; Wang L; Su B; Zeng W; Jiang T; Zhang T; Sun G; Wu H
    J Int Med Res; 2020 Mar; 48(3):300060519889270. PubMed ID: 31852373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
    Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers.
    Kimura H; Ohkawa K; Miyazaki M; Sakakibara M; Imanaka K; Tamura T; Sueyoshi H; Takada R; Fukutake N; Uehara H; Ashida R; Ioka T; Nakazawa T; Nakanishi K; Katayama K
    Hepatol Int; 2017 Jan; 11(1):105-114. PubMed ID: 27766479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
    Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
    Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
    Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
    PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma.
    Shimada M; Takenaka K; Fujiwara Y; Gion T; Kajiyama K; Maeda T; Shirabe K; Sugimachi K
    Cancer; 1996 Nov; 78(10):2094-100. PubMed ID: 8918402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
    Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Park WH; Shim JH; Han SB; Won HJ; Shin YM; Kim KM; Lim YS; Lee HC
    J Vasc Interv Radiol; 2012 Jul; 23(7):927-36. PubMed ID: 22633621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
    Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
    J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
    Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
    Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma.
    Gómez-Rodríguez R; Romero-Gutiérrez M; Artaza-Varasa T; González-Frutos C; Ciampi-Dopazo JJ; de-la-Cruz-Pérez G; Sánchez-Ruano JJ
    Rev Esp Enferm Dig; 2012 Jun; 104(6):298-304. PubMed ID: 22738699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.